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Abstract 
Background: The LRP1 (CR9) domain and, in particular, the sequence Gly1127-Cys1140 (P3) plays a critical role in the 
binding and internalization of aggregated LDL (agLDL). We aimed to evaluate whether immunization with P3 reduces 
high-fat diet (HFD)-induced atherosclerosis.  
Methods: Female New Zealand White (NZW) rabbits were immunized with a primary injection and four reminder 
doses (R1-R4) of IrP (irrelevant peptide) or P3 conjugated to the carrier. IrP and P3-immunized rabbits were 
randomly divided into a normal diet group and a HFD-fed group. Anti-P3 antibody levels were determined by ELISA. 
Lipoprotein profile, circulating and tissue lipids, and vascular pro-inflammatory mediators were determined using 
standardized methods while atherosclerosis was determined by confocal microscopy studies and non-invasive imaging 
(PET/CT and Doppler ultrasonography). Studies treating human macrophages (hMΦ) and coronary vascular smooth 
muscle cells (hcVSMC) with rabbit serums were performed to ascertain the potential impact of anti-P3 Abs on the 
functionality of these crucial cells. 
Results: P3 immunization specifically induced the production of anti-P3 antibodies (Abs) and did not alter the 
lipoprotein profile. HFD strongly induced cholesteryl ester (CE) accumulation in the aorta of both the control and IrP 
groups, and their serum dose-dependently raised the intracellular CE of hMΦ and hcVSMC, promoting TNFR1 and 
phospho-NF-kB (p65) overexpression. These HFD pro-inflammatory effects were dramatically decreased in the aorta 
of P3-immunized rabbits and in hMΦ and hcVSMC exposed to the P3 rabbit serums. Microscopy studies revealed that 
P3 immunization reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the 
atherosclerotic extent and lesion area in the aorta. PET/CT and Doppler ultrasonography studies showed that the 
average standardized uptake value (SUVmean) of the aorta and the arterial resistance index (ARI) of the carotids were 
more upregulated by HFD in the control and IrP groups than the P3 group. 
Conclusions: P3 immunization counteracts HFD-induced fatty streak formation in rabbits. The specific blockade of 
the LRP1 (CR9) domain with Anti-P3 Abs dramatically reduces HFD-induced intracellular CE loading and harmful 
coupling to pro-inflammatory signaling in the vasculature. 
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Cardiovascular disease (CVD) is the leading 
cause of death, the dominant cause of which is 
atherosclerosis, which mainly occurs in the intima of 
several middle-sized and large arteries. Intimal 
thickening, occurring during the first step of 
atherosclerosis, is majorly associated with low density 
lipoprotein (LDL) retention by the proteoglycans of 
the arterial intima. Intimal retained LDLs undergo 
LDL aggregation (agLDL) and fusion which is a key 
event in the progression of atherosclerosis. [1–3]. 
AgLDL interacts with the receptor low-density 
lipoprotein receptor-related protein 1 (LRP1), and 
LRP1-mediated agLDL uptake causes intracellular 
cholesteryl ester (CE) loading and foam cell formation 
in human coronary vascular smooth muscle cells [4–6] 
and macrophages [7,8].  
LRP1 receptor is a signaling mediator that exerts 
essential cytoprotective and anti-inflammatory func-
tions. Therefore, its potential pathological functions 
could not be overcome by LRP1 silencing. This 
strategy will indeed cause deleterious effects in 
macrophage and VSMC functionality, which both 
depend on proper LRP1 β-chain signaling [9–11]. 
LRP1 β-chain is phosphorylated on the distal NPxY 
motif of the by PDGF-BB mitogenic signaling, and this 
modulates VSMC proliferation[12,13]. LRP1 signaling 
is also essential to limit lesional apoptosis and 
inflammation through the regulation of monocyte 
recruitment, macrophage apoptosis susceptibility, 
and efferocytosis [14,15]. In line, it has been 
thoroughly shown that disabling LRP1 tyrosine 
phosphorylation causes macrophage intracellular 
lipid accumulation and the anomalous clearance of 
apoptotic cells, resulting in accelerated atherosclerosis 
[16]. In addition to signaling mediated by the LRP1 b 
chain, signaling induced through the binding of its 
a-chain to extracellular ligands also seems to be 
essential for optimal vascular function. The 
atheroprotective induction of Wnt5a mediated by 
extracellular TGF-β in macrophages requires LRP1 α 
chain [17]. Apolipoprotein E-mediated interleukin-1 
receptor associated kinase-1 (IRAK-1) signaling that 
downregulates NF-κB-induced inflammation requires 
the binding of Apolipoprotein E to LRP1 α chain [18]. 
The binding of protease-inhibitor complexes to 
LRP1 α chain inhibit the NF-kB inflammatory 
response, and induce a cytoprotective effect through 
phosphorylation of Akt and ERK1/2 protein kinases 
[19–21]. NF-kB is a key player involved in the 
development and progression of inflammation in 
different tissues, including the vasculature [22]. A 
vascular mediator in NF-kB activation is tumor 
necrosis factor-alpha receptor -1 (TNFR1), which 
enhances arterial wall chemokine and adhesion 
molecule expression, as well as smooth muscle cell 
proliferation and migration in atherosclerosis [23]. 
We have previously identified one peptide 
sequence (P3: H-GDNDSEDNSDEENC-NH2) (Gly 
1127–Cys1140) in the CR9 domain of LRP1 that is 
crucial for its interaction with aggregated LDL [24]. 
We showed that polyclonal antibodies generated 
against P3 sequence (Anti-P3 Abs), located in the CR9 
domain, efficiently blocked hcVSMC-foam cell forma-
tion. It is important to note that the CR8/CR9 tandem 
is the only pair of consecutive CR modules from the 
LRP1 cluster II that shows only negligible affinity for 
serpins such as plasminogen activator inhibitor-1 
(PAI-1) and protease nexin 1 (PN1) [25]. This makes 
CR9 an ideal target to counteract LRP1-AgLDL 
interactions without altering the binding of other 
essential ligands, such as protease-inhibitor com-
plexes, which are key inhibitors of pro-inflammatory 
signals. 
On the basis of these previous results, we 
considered a challenge within the cardiovascular field 
to study the anti-atherosclerotic efficacy of anti-P3 
antibodies in a translational in vivo model, similar to 
humans in the cholesterol-carried lipoprotein profile. 
In the rabbit model of HFD-induced atherosclerosis, 
cholesteryl esters are mainly carried by ApoB-100 
lipoproteins and there is an elevated participation of 
SMCs in fatty streak lesions [26]. In addition, this 
model has been previously validated to study the 
effects of HDL on fatty streak formation and evolution 
[27] as well as to study vascular inflammation by the 
mainstay imaging technique 18F-FDG/PET [28].  
The aim of this work was to study the potential 
therapeutic relevance of a LRP1 (CR9)-specific 
blockade with anti-P3 Ab to counteract HFD-induced 
atherosclerosis. Our results showed that anti-P3 
antibodies reduced HFD-induced cholesteryl ester 
accumulation and pro-inflammatory signaling in the 
aorta. The potent anti-inflammatory efficacy of 
anti-P3 Abs allowed for the corroboration of the 
treatment’s efficacy via non-invasive imaging 
techniques, such as 18F-FDG/PET and Doppler 
ultrasonography, which provided a high translational 
impulse to this innovative, anti-atherosclerotic, 
potentially therapeutic tool.  
Methods 
Peptide Synthesis and conjugation 
The P3 peptide used to immunize rabbits 
contained the following sequence GDNDSEDNSDEE-
NC corresponding to the amino acids 1127 to 1140 
located in LRP1 cluster II (domain CR9) [24]. The P3 
sequence corresponds to an area of high homology 





between human and rabbit LRP1, with the difference 
that the asparagine (N) in humans was replaced by a 
serine (S) in the rabbit protein. In addition, the amino 
acid C1148 in the rabbit sequence (GDNDCEDNSDEE-
NC) was replaced by S to achieve greater peptide 
immunogenic effectiveness. The irrelevant peptide 
(IrP) has the same sequence than P3 but with amino 
acids in D-enantiomer configuration. Both peptides 
were synthesized by the Laboratory of Proteomics & 
Protein Chemistry, Department of Experimental & 
Health Sciences, Pompeu Fabra University, by the 
solid-phase method using a Prelude peptide 
synthesizer (Protein Technologies, Inc.). Peptides 
were purified by high-performance liquid chromato-
graphy (HPLC, Waters 600) using UV detection at 254 
nanometers (Waters 2487) and characterized by mass 
spectrometry (Applied Biosystems 4700 Proteomics 
Analyser). 
Peptides were conjugated to the transporter 
molecule Keyhole limpet haemocyanin (KLH) for 
immunizations and with bovine serum albumin (BSA) 
for ELISAs. The conjugation of peptide to KLH and 
BSA (Sigma, St. Louis, MO) was performed as 
previously described [29]. Peptide–KLH conjugates 
were used for rabbit immunization and peptide-BSA 
conjugates for substrate in the immunoassay ELISA to 
detect specific anti-P3 Abs in the rabbit serum.  
Animal model 
Thirty New Zealand White (NZW) rabbits from 
the San Bernardo Farm animal centre (Navarra, Spain) 
weighing 1.8-2 kg (6-7 months-age) were used in this 
study. Rabbits were housed in a Tecniplast R-Suite 
cage with a surface area of 4.264 cm2. Housing 
temperature was maintained at 21°C, relative humid-
ity ranged between 40-60%, and the light period was 
12 hours a day. All animals had food and water ad 
libitum. Experimental procedures were approved by 
the Ethics Committee of Animal Experimentation of 
the Vall d'Hebrón Institute of Research with 
registration number 46/17, and performed in 
accordance with Spanish legislation and also with the 
European Union directives (2010/63/ EU). 
Animals were fed the "chow" R-01 diet from 
Granja San Bernardo with the following formulation: 
17.3% protein, 16.7% fibre and 3% fat; or HFD 
TD.88137 (42% from fat) from ENVIGO. Animals 
were acclimated for one week before the first 
immunization and immunized with a primary 
injection and four reminder doses (R1-R4) of IrP 
(irrelevant peptide) (IrP group; N=12) or P3 (P3 
group; N=15) conjugated to the carrier every 21 days. 
An additional group of rabbits was injected with 
carrier alone (control group; N=3). The four doses of 
IrP or P3 antigen conjugated with KLH (or carrier) 
were administered subcutaneously (138 µg/kg, 
maximum volume 150 µL) every 21 days. For the first 
immunization, IrP or P3-KLH peptides were 
emulsified in Freund's Adjuvant Complete, and the 
rest of the immunizations were done using IrP or 
P3-KLH conjugated in Freund's Incomplete Adjuvant 
(both from Sigma Aldrich). During the immunization 
period, the animals were fed a chow diet.  
Starting at the R4 time point, IrP and 
P3-immunized rabbits were randomly divided into 
normal diet group and high-fat diet (HFD)-fed group. 
Twelve rabbits (N=6 Irp-injected and N=6 P3-injected) 
continued fed on the chow diet, whereas fifteen 
rabbits (N=6 IrP-injected and N=9 P3-injected ) and 
one rabbit control group (N=3 injected with carrier 
alone) received HFD for 30 days (supplemental Figure 
S1). In pre- and post-diet time points, animals were 
weighed, serum levels of specific anti-P3 Abs were 
determined by ELISA, and animals were submitted to 
PET-CT and carotid Doppler ultrasonography 
imaging studies. After imaging studies, animals were 
euthanized and aortas, carotids and liver were 
dissected and processed for molecular, confocal and 
immunohistochemical studies.  
Determination of circulating lipids and the 
lipid content in lipoproteins 
Total plasma cholesterol, choline-containing 
phospholipid, triglyceride and NEFA levels were 
enzymatically determined using commercial kits 
adapted to a COBAS 501 autoanalyzer (Roche 
Diagnostics, Rotkreuz, Switzerland). VLDL, LDL and 
HDL lipoproteins were isolated by sequential 
ultracentrifugation at 100,000 g for 24 h at a density of 
1.006, 1.019-1.063 and 1.063-1.21 g/ml, respectively, 
using an analytical fixed angle rotor (50.3, Beckman 
Coulter) [30]. The composition of each lipoprotein, 
including total and free cholesterol, triglycerides and 
phospholipids, was determined by commercial 
methods adapted to the COBAS 501 autoanalyzer. 
Lipoprotein protein concentrations were determined 
by the bicinchoninic acid method (Termo Scientific, 
Rockford, IL). Lipoprotein composition was used to 
calculate the total mass of each lipoprotein. 
Detection of specific antibodies 
We standardized immunoELISAs to detect 
specific antibodies against P3 peptides. Briefly, all 
sera were analysed using 96-well polystyrene plates 
(Ref 442404 Maxisorp, NUNC, Labclinics, Spain) 
coated with peptide-BSA and BSA as a control for the 
detection of unspecific antibodies. ELISA plates were 
incubated with several serum dilutions for 90 
minutes, and after washes, anti-rabbit IgGs 
conjugated to peroxidase (Ref 170-6515, BioRad, 





Spain) was added to detect the antigen-antibody 
complexes. ELISA was revealed using OPD substrate 
(Ref P9187, Sigma Aldrich, Spain), and the absorbance 
was read in a Multilabel reader Victor3 (Perkin Elmer, 
Turku, Finland) at 450 nm. The absorbances obtained 
were adjusted to a 4PL curve to calculate the IC50. The 
parameter 1/IC50 was taken as the antibody titer. 
Isolation of Rabbit Aortic Smooth Muscle Cells 
 Rabbit aortic smooth muscle cells (rSMCs) were 
obtained by gentle scraping of the medial layer of 
New Zealand White rabbit aortas after endothelial 
layer removal. Cells were incubated at 37°C in a 
humidified atmosphere of 5% CO2 in Ham's 
F12-DMEM (8:2) supplemented with 20% foetal calf 
serum, 100 U/mL penicillin and 0.1 mg/mL 
streptomycin. To maintain exponential growth, cells 
were subcultured by trypsinization and seeded at a 
density of 10 000 cells/cm2. rSMCs were identified by 
their growth behaviour, morphology, and immuno-
fluorescence. Immunocytochemical identification of 
cells was performed by specific monoclonal anti-
bodies for α-smooth muscle cell and von Willebrand 
factor. Cells were fixed with ice-cold methanol at 20°C 
for 5 minutes. A solution of BSA at 1% in PBS was 
used as a blocking agent. Monoclonal antibodies 
against LRP1 (Fitzgerald, 10R-L107c) and polyclonal 
antibodies obtained from P3-immunized rabbits were 
diluted in PBS/1% BSA/0.01% Triton X-100. Finally, 
FITC-conjugated goat anti-mouse IgG and 
FITC-conjugated goat anti-rabbit IgG were used as 
secondary antibodies. Images were captured and 
analysed on a Leica inverted fluorescence confocal 
microscope (Leica TCS SP2-AOBS). 
Isolation of human macrophages primary 
cultures  
Human macrophages (hMΦ) were obtained from 
buffy coats of healthy blood donors. Cells were 
applied on 15 ml of Ficoll-Hypaque and centrifuged at 
300 g for 1 hour at 22°C, with no brake. Mononuclear 
cells were obtained from the central white band of the 
gradient, exhaustively washed in Dulbecco's phos-
phate buffer saline, and suspended in RPMI medium 
(Gibco) supplemented with 10% human serum AB 
(Sigma). Cells were left 7 days in culture and allowed 
to differentiate into macrophages by changing the cell 
culture media (RPMI supplemented with 10% human 
serum AB, 100 units/ml penicillin and 100 µg/ml 
streptomycin) every 3 days. 
Culture of coronary human vascular smooth 
muscle cells  
Human coronary vascular smooth muscle cells 
(hVSMC) were obtained from the medium layer 
isolated from macroscopically healthy coronary artery 
segments collected from patients undergoing cardiac 
transplantation at Hospital de la Santa Creu i Sant Pau 
(Barcelona, Spain). hVSMCs were isolated by a 
modification of the explant technique, as described 
previously [4–6]. The explants were incubated at 37 °C 
in a humidified atmosphere of 5% CO2. After 1week, 
the cells start to migrate from the explants and 
proliferate, covering the floor of the culture well. The 
medium was exchanged every 3 days after the onset 
of cell outgrowth; a significant outgrowth was 
reached after 10 days. Tissue fragments were collected 
with forceps and placed in a new dish with fresh 
medium. The cells that remained in the dish were 
cultured until confluence. For characterization, cells 
were seeded in cover-slips and grown to confluence. 
Cell quiescence was induced by maintaining the cell 
culture for 24 h in a medium with 0.2% FCS or for 48 h 
in a medium with 0.4% serum. All experiments used 
serum-deprived cells between passages 4 and 6; 
VSMCs at these passages appeared as a relatively 
homogeneous population, showing a hill-and-valley 
pattern at confluence. Western blot analysis for 
specific differentiation markers revealed high levels 
of-actin (45 kDa) and calponin (33 kDa). Cell 
monolayers were grown in medium 199 
supplemented with 20% FBS, 2% human serum, 2 
mmol/literL-glutamine, 100 units/ml penicillin G, 
and 100g/ml streptomycin. The study was approved 
by the Institutional Ethics Committee at Hospital de la 
Santa Creu i Sant Pau and conducted in accordance 
with the Declaration of Helsinki. 
Treatment of hMΦ and hcVSMC with rabbit 
serums 
Quiescent hMΦ and hcVSMC were exposed to 
increasing concentrations of serum (0.25%, 0.5% and 
1%) from the different rabbit groups for two hours. In 
some experiments, quiescent hMΦ were exposed to 
aggregated LDL (100 µg/mL, 2 hours), generated as 
previously described [4–6] in the presence of 
increasing concentrations (1%, 5% and 10%) of chow 
serum from the different group of rabbits. Following 
the serum incubation period, cells were exhaustively 
washed and harvested in NaOH 0.1 M or lysis buffer 
for lipidic and Western blot analysis.  
18F-FDG PET/CT and image analysis 
An injection of 18F-FDG (0.5 mCi/kg) was 
administered through a catheter in the marginal vein 
of the ear of each animal. The image study was 
performed on a Siemens Biograph mCT S64 hybrid 
PET/CT instrument. We carried out an angiographic 
PET/CT study at 120 and 180 minutes, which allowed 
the anatomical and metabolic localization of the 





studied structures. The CT and PET studies were 
recorded for 5-6 seconds and 15 minutes, respectively.  
Acquisition parameters 
Thoracic-abdominal imaging studies of the 
heart, great vessels and abdominal aorta in only one 
bed position (15 minutes) were performed at the 
maximum resolution of the PET/CT equipment (1.5 
mm in the PET and 0.5 mm in the CT). 
CT characteristics (attenuation correction) 
AngioCT characteristics: An angiographic study 
was performed before PET acquisition. VISIPAQUETM 
(iodixanol) contrast was used and injected at 
0.7ml/sec.  
Image analyses 
The co-registration of both studies (PET and CT) 
was automatically carried out by the Software of the 
Siemens Biograph mCT S64 hybrid PET/CT 
equipment. PET/CT data were displayed in axial 
planes on a Syngovia (Siemens) workstation. Mean 
standard uptake value (SUV)s were recorded on 
contiguous axial slices of the aorta superior, central 
and inferior (one ROI in each area).  
The corresponding SUV units were calculated in 
each animal. These units allow the comparison and 
standardization of the emission values of each 
structure studied, including decay correction between 
dual time-point images. PET/CT outcome variables 
were the maximum and averaged SUVs. 
Ultrasonography 
 Ultrasonography was performed with a 
Mindray M7 device (Shenzen Mindray Bio-medical 
Electronics, Shenzen, PRC) and a 7.5 MHz central 
frequency lineal probe. All animals were anaesthe-
tized with propofol and maintained with iIsofluorane 
(2-3% in fresh air) to respect their welfare and to avoid 
tachycardia or stress-induced pulse frequency.  
Ultrasonographic exams were performed for 
carotid arteries. The morphology of carotid arteries 
was measured using B mode images, followed by 
colour and pulsed wave Doppler analysis to check the 
blood flow. The specific location at the internal and 
external carotid division was selected following 
previously published reference [31], assuming that 
this location is a target for lipid deposits. 
The parameters included were systolic and 
diastolic velocities, as well as arterial resistance index 
(ARI). ARI=(Systolic velocity-Diastolic velocity)/ 
Systolic velocity). In all the ultrasonographic 
parameters, three different measurements were 
performed in each image, and the mean value was 
used for parameter calculation. The software used for 
measurements was that included in the ultrasound 
device, and mathematical calculations were obtained 
in Excel format. 
Preparation of histological sections and 
immunohistochemistry 
At necropsy, the aorta, carotids and liver were 
dissected. The aorta was cleaned from external fat and 
divided into two sections: thoracic aorta, from the 
aortic arc to the hepatic aorta, and abdominal aorta, 
from the hepatic aorta to the bifurcation of the iliac 
aortas (Supplemental Figure S2). As shown in 
Supplemental Figure 2, the first 2 cm section of the 
thoracic aorta was opened by a longitudinal incision. 
The rest of the aorta was divided into 1cm pieces. 
Alternatively, each piece was frozen and sectioned for 
histological and molecular studies. Carotids were 
frozen and kept at -80 ºC for further analysis of lipid 
composition. 
Longitudinally open sections of aorta were fixed 
in 4% paraformaldehyde-PBS solution for fatty streak 
detection and quantification using Herxheimer’s 
staining method. Samples for immunohistochemistry 
were transversally cut with a cryostat in serial 
sections of 5 µm and mounted in gelatinized slides. 
Transversally cut sections were also stained with 
Herxheimer’s staining method to detect lipids. Images 
were captured with an Olympus Vanox AHBT3 
microscope, and digitalized using a Sony 3CCD 
camera.  
Confocal microscopy studies 
Arteries were dissected, immersed in cell 
maintenance media, examined under low magnifica-
tion with a zoom stereo microscope and classified 
according to the criteria of the American Heart 
Association (AHA). At this point, samples were used 
for immunohistochemistry or were stained with 
Masson’s trichromic to identify vascular structures. 
Serial sections (5 µm thick) were immunostained with 
Phalloidin-488 (to identify smooth muscle cells), and 
RAM11 (Dako M063301-8), NF-kB p65 (C22B4) (Cell 
Signalling; #4764) and TNFR1 (MyBiosource MBS8409 
39) with secondary antibody Alexa Fluor 633 IgG). 
Images were recorded on a Leica inverted fluores-
cence confocal microscope (Leica TCS SP2-AOBS, 
Germany). Arteries were viewed with HCX PL APO 
20x/0,75 IMM Corr CS2 objective. Fluorescent images 
were acquired in a scan format of 1024 x 1024 pixels 
and were processed with the Leica Standard Software 
TCS-AOBS. Controls without primary antibody 
showed no fluorescence labelling. 
Image analysis 
Image analysis was performed using Visilog 5.4 
software (Noesis, France) to quantify the extent of the 





lesions, and the results were given as the percentage 
of the total aortic area covered by lipid. Images were 
captured with a Vanox AHBT3 microscope (Olym-
pus) and digitized using a DXC-S500 camera (Sony) at 
x200 magnification. Six different sections were 
analysed per animal, and six animals were analysed 
per group. The results were shown as the mean ± SD. 
Western blotting analysis 
Blots were incubated with antibodies against 
mouse LRP1 (β-chain, clone 5A6 RDI-PRO61066), 
SREBP-2 (Santa Cruz Biotechnology; sc-13552), 
phospho-NF-kB p65 (Cell Signaling; #3039), NF-kB 
p65 (C22B4) (Cell Signalling; #4764) and TNFR1 (My-
Biosource MBS840939) Protein extracts (10 μg) were 
loaded, resolved on 12% SDS-PAGE and transferred 
to nitrocellulose membranes (BioRad). Signal detec-
tion was carried out with the ECL immunoblotting 
detection system (GE Healthcare) and the results were 
quantitatively analyzed using Chemidoc (BioRad). 
Equal protein loading in each lane was verified by 
incubating blots with monoclonal antibodies against 
β-actine (Cell Signaling Technology, Inc, #3700S). 
Lipid analyses and determination of aortic, 
carotid and hepatic neutral lipid content Aorta (10 
mg), liver (2.5 mg) and the whole extracted carotid 
were homogenized in NaOH 0.1 M. Lipids were 
extracted and quantified as previously described [4–
6]. Cholesteryl esters (CE) triglycerides (TG) and free 
cholesterol (FC) were analysed by thin-layer 
chromatography (TLC). The organic solvent was 
removed under an N2 stream, the lipid extract was 
redissolved in dichloromethane, and one aliquot was 
partitioned by TLC which was performed on silica 
G-24 plates. Different concentrations of standard (a 
mixture of cholesterol, triglycerides and cholesterol 
palmitate) were applied to each plate. The chromato-
graphic developing solution was heptane/ 
diethylether/acetic acid (74:21:4, vol/vol/vol). Spots 
corresponding to CE and FC were quantified by 
densitometry against the standard curve of 
cholesterol palmitate and cholesterol, respectively, 
using a computing densitometer. 
Statistical analysis 
The results were expressed as the mean ± SD. 
Differences between study groups were analysed 
using one-way analysis of variance (ANOVA) 
followed by a post-hoc Tukey b-test. In the image 
analysis, Student’s t-test for paired samples was used 
to compare differences between baseline and HFD 
feeding PET/CT parameters in each experimental 
group. The statistical software R (www.r-project.org) 
was used for all statistical analyses. Differences were 
considered statistically significant when P < 0.05.  
Results 
P3- Immunization induces the production of 
anti-P3 antibodies in rabbits 
ELISA analyses showed the absence of specific 
antibodies against P3 in the serum of both the control 
(Figure 1A) and IrP-injected groups (Figure 1B) as 
well as its presence in P3-immunized rabbits serum 
(Figure 1C). Anti-P3 Abs levels were maintained in 
P3-immunized rabbits serum throughout the entire 
diet period. Previous studies focusing on the 
functional evaluation of anti-P3 Abs showed their 
efficacy in reducing foam cell formation through the 
blockade of the LRP1/agLDL interaction [24]. Here, 
confocal microscopy studies revealed that Abs in the 
P3-immunized rabbits serum hybridized with the 
LRP1 with a similar efficiency as commercial 
anti-LRP1 Abs in rabbit aortic vascular smooth muscle 
cells (rSMCs) (Figure 1D). None of the sera showed an 
unspecific response when only BSA without a 
conjugated peptide, was used as an antigenic source 
in ELISA (data not shown). 
Anti-P3 Abs counteract HFD-induced 
atherosclerosis in rabbits 
En face preparations of the thoracic aorta showed 
that HFD feeding in rabbits induced a high 
percentage of occupation of the aortic vasculature 
with fatty streak lesions in the control and IrP groups 
but not in the P3-immunized group (Figure 2A and 
2B). Immunohistochemistry studies revealed a high 
percentage of lipids and macrophages in the arterial 
intima of control and IrP-immunized rabbits that was 
strongly reduced in P3-immunized rabbits (Figure 
2C). Finally, confocal microscopy studies showed an 
elevated presence of α-actin positive cells in the 
intima of the initial lesions in control and IrP groups 
that was almost completely absent in the P3 group 
(Figure 3A). Both VSMC (falloidin positive cells in 
red) and macrophages (RAM11 positive cells in green) 
coexist in the intimal thickening of initial 
atherosclerotic lesions (Figure 3B). Taken together, 
these results demonstrate that anti-P3 Abs limit 
monocyte recruitment and VSMC migration, thus 
preventing early atherosclerotic formation in rabbits.  
Anti-P3 Abs reduce cholesteryl ester 
accumulation and pro-inflammatory signals 
induced by HFD in the vasculature of rabbits 
without altering serum lipid levels or the 
lipoprotein profile 
Circulating levels of cholesterol, phospholipid 
and NEFAs, but not triglycerides, were strongly 
higher in HFD- compared to chow fed rabbits, but 
there were no differences in P3 compared to control 





groups (Suplemental Figure S3). VLDL, LDL, or HDL 
lipoprotein masses and triglyceride (TG), 
phospholipid (Ph), free cholesterol (FC), cholesteryl 
esters (CE) and protein levels in lipoprotein fractions 
were similar among the three groups (Figure 4). These 
results clearly indicate that P3 immunization did not 
alter the plasma lipid levels and that, in rabbits, 
cholesteryl esters are mainly carried by LDL and 
VLDL lipoproteins in all rabbit groups. There were no 
differences on weight gain according to diet or 
between groups (supplemental Figure S4). 
Consistent with the high impact of HFD on the 
VLDL and LDL cholesteryl ester content, HFD 
increased CE accumulation to a much higher extent in 
the aorta of control and IrP groups than in the 
P3-immunized group (Figure 5A). There were no 
differences in the low TG or FC content in the 
vasculature between groups. In the liver, HFD 
strongly increased CE, TG and FC content with no 
differences between the groups (Figure 5B). 
Molecular studies have shown that HFD 
increased LRP1 levels in the aorta (Figure 6A,B), as 
previously shown in this and other models by the 
group [4,32]. The upregulatory effect of HFD on LRP1 
was not observed in the aorta of P3-immunized 
rabbits, confirming the vascular LRP1 upregulation 
by cholesteryl esters in this particular experimental 
setting.  
Molecular studies combined with confocal 
studies have shown that HFD raises TNFR1 (Figure 
6A,C,D)and NF-kB (p65) (Figure 6A,E,F) protein 
levels in the aorta of the control and IrP groups but 
not in the P3-immunized group. These results indicate 
that anti-P3 are highly efficient inhibiting cholesteryl 
ester accumulation and pro-infammatory signaling in 
the vasculature of rabbits. 
HFD serum from the P3-immunized rabbits, 
different from that of the control and 
IrP-immunized rabbits, failed to induce 
intracellular cholesteryl ester accumulation 
and pro-inflammatory signaling in human 
macrophages and human coronary vascular 
smooth muscle cells  
The treatment of human macrophage (hMΦ) and 
human coronary vascular smooth muscle cell 
 
 
Figure 1. P3 immunization raises serum levels of specific anti-P3 antibodies. (A) Graphs showing the results of standardized enzyme-linked immunosorbent assay 
(ELISA) in pre-serum and serum at the check points (Check1 and Check2) from control (A), IrP- (B) and P3-treated rabbits (C) against P3-BSA used as antigenic source. Results 
are shown as mean±SD. Control (N=3); IrP (N=12); P3 (N=15) (D) Confocal images of rabbit SMCs exposed to serum from P3-treated rabbits (middle panel) or to commercial 
anti-LRP1 (right panel). 





(hcVSMC) with chow serum from the control, IrP or 
P3 groups (1%, 2 hours) failed to increase intracellular 
cholesteryl ester content in hMΦ (Figure 7A) and 
hcVSMC (Figure 8A). In contrast, treatment of cells 
with HFD serum (1%, 2 hours) from the control and 
IrP groups (but not the P3 group) dramatically raised 
the intracellular CE content in hMΦ (Figure 7A) and 
hcVSMC (Figure 8A). HFD serum from control and 
IrP groups (but not the P3 group) dose-dependently 
raised the intracellular CE content of both hMΦ and 
hcVSMC (supplemental Figure S5). Treatment with 
chow serum from P3-immunized rabbits but not from 
control or IrP-injected rabbits dose-dependently 
reduced intracellular CE accumulation in hMΦ 
exposed to aggregated LDL (100 µg/mL, 2 hours) 
(supplemental Figure S6). 
Concurrently with HFD serum-induced 
intracellular CE accumulation, LRP1 protein levels 
were augmented while those of sterol regulatory 
element binding protein 2 (SREBP-2) decayed in hMΦ 
and hcVSMC exposed to (control and IrP)-HFD 
serums (1%, 2 hours) but not in cells exposed to P3 
serum under the same experimental conditions 
(Figure 7B,C,D and 8B,C,D respectively). These results 
are in line with the capacity of intracellular cholesteryl 
esters to stimulate LRP1 transcription through 
SREBP-2 downregulation previously described by our 
group [4,33,34]. There were no differences in LRP1 
and SREBP-2 protein levels between cells exposed to 





Figure 2. P3 immunization reduces HFD-induced atherosclerotic burden. (A) Representative images of longitudinally open sections of aorta stained with Herxheimer 
in control, IrP and P3-immunized rabbits fed either chow or HFD. (B) Graph showing quantification of atherosclerotic burden in HFD-fed rabbits from control (N=3), IrP (N=6) 
and P3 (N=9). Results are shown as mean±SD of 8 aortic sections/rabbit. #P<0.005, P3 versus control and IrP groups. (C) Representative immunohistochemical images of lipid and 
macrophage staining in cross-sections of aortas from control and P3-immunized rabbits, both on HFD m: media; i: intima. 






Figure 3. P3 immunization reduces HFD-induced SMC accumulation in the arterial intima. Representative confocal microscopy images of SMCs detected with 
anti-a-actin antibodies in cross-sections of aortas from control and P3- immunized rabbits (A) and of SMC detected with falloidin and macrophages detected with anti-RAM 
antibodies (B). Fluorescent images were acquired in a scan format of 1024 x 1024 pixels and were processed with the Leica Standard Software TCS-AOBS. m: media; i: intima. 
 
Figure 4. P3 immunization did not induce alterations in lipoprotein mass subclasses or lipoprotein profile of HFD fed rabbits. VLDL, LDL and HDL were 
isolated by sequential ultracentrifugation and their composition in terms of total, free cholesterol, triglycerides, phospholipids and protein were determined as explained in 
methods. Lipoprotein composition was used to calculate the total mass of each lipoprotein. Results are shown as mean±SD of control (N=3), IrP (N=6) and P3-immunized rabbits 
(N=9). 






Figure 5. P3 immunization reduces HFD-induced cholesterol accumulation in the aorta but not in the liver. Representative thin-layer chromatography of aorta 
(A) and liver (B). Bar graphs showing the quantification of cholesteryl ester (CE), triglycerides and free cholesterol content of aorta and liver. Results are expressed as µg 
cholesterol per mg protein and shown as mean ± SD in chow IrP (N=6), chow P3 (N=6), HFD Ctr (N=3), HFD IrP (N=6) and HFD P3 (N=9). *P<0.005 versus chow diet; 
#P<0.005 versus control or IrP-rabbits. 
 
Figure 6. P3 immunization reduces aortic pro-inflammatory mediators in the aorta. Representative Western blot analysis of LRP1, TNFR1, pNF-kB (p65), total 
NF-kB (p65), and β-actin bands (A) and bar graphs showing band quantification of LRP1 and TNFR1 normalized by a-actin (B,C) and pNF-kB (p65)/total NF-kB (p65) ratio (E). 
Results are shown as mean ± SD in chow IrP (N=6), chow P3 (N=6), HFD Ctr (N=3), HFD IrP (N=6) and HFD P3 (N=9). *P<0.005 versus chow diet; #P<0.005 versus control 
or IrP-rabbits. Representative confocal microscopy images of TNFR1 (D) and NF-kB levels (F) in aortic samples from the different groups. Scale bar = 50 µm. 






Figure 7. HFD serum from control and IrP serum, but not P3 serum, dramatically increased intracellular CE and pro-inflammatory mediators in human 
macrophages. Quiescent human macrophages (hMΦ) were exposed to serum from the different groups (0.5%, 2 hours). Cells were then exhaustively washed and collected in 
NaoH 0.1N for lipid extraction or in lysis buffer for Western blot analysis. A) Representative TLC and bar graphs showing the cholesteryl ester (CE) /free cholesterol ratio. 
Representative Western blot analysis of LRP1, SREBP-2, TNFR1, pNF-kB (p65), total NF-kB (p65), and a-actin bands (B) and bar graphs showing band quantification of LRP1, 
SREBP-2 and TNFR1 normalized by a-actin (C,D,E) and pNF-kB (p65)/total NF-kB (p65) ratio (F). Results are shown as mean ± SD of three experiments performed in duplicate. 
*P<0.005 versus chow serum; #P<0.005 versus control or IrP-serums. 
 
Our molecular studies showed that HFD serum 
(from the control and IrP groups) promote a much 
higher induction of crucial inflammatory mediators, 
such as TNFR1 and pNF-kB (p65), than a chow diet in 
hMΦ (Figure 7B,E,F) and hcVSMC (Figure 8B,E,F). 
However, P3 immunization efficiently restricted the 
HFD serum pro-inflammatory effects in cells to the 
levels found in cells exposed to chow serums. These 
results highlight the crucial role of Anti-P3 Abs in 
counteracting HFD-induced pro-inflammatory 
signaling coupled with the intracellular cholesteryl 
ester loading of human macrophages and human 
coronary vascular smooth muscle cells. 
PET/CT imaging studies show that Anti-P3 
Abs reduce 18F-FDG uptake in the aorta of 
rabbits  
PET-CT metabolic images were performed and 
analyzed at 120 and 180 minutes after the intravenous 
administration of 18-FDG in the three groups before 
their submission to a specific diet. After 31 days of 
specific diet feeding, subsequent new metabolic 
images were obtained and analyzed at 120 and 180 
minutes. Maximal-intensity projections (MIP) and 
orthogonal slices were analyzed in fused 
morpho-metabolic images to identify the aortic tract, 
and, in the axial plane, three sections were selected for 
SUV measurements: upper, middle and lower. A 
circular region of interest (ROI) was drawn following 
anatomical limits in each section, from which SUVmean 
was obtained. A progressive decrease in aortic activity 
was observed as a function of time, which was 
attributed to the clearance of the vascular background 
activity. The acquisition that best separated the 
groups was that performed at 120 minutes. The 
measurements in the three segments of the aorta 
showed that the highest 18F-FDG uptake activity 
occurred in the upper region while it decreased in the 
middle region and practically disappeared in the 
lower region. HFD significantly increased SUVmean in 





the upper and middle regions of the aorta of control 
groups, as previously shown [35]. In contrast, in the 
P3-immunized rabbits, HFD only slightly induced 
SUVmean in these aortic regions (Figure 9). Moreover, 
rabbits on the chow diet did not show alterations in 
post-diet versus pre-diet SUVmean values (supple-
mental Figure S7). The high impact of Anti-P3 Abs on 
aortic 18F-FDG uptake confirmed molecular, confocal 
and immunohistochemical results obtained in the 
present study showing an elevated anti-inflammatory 
potential of anti-P3 Abs in macrophages and smooth 
muscle cells in the vasculature.  
Doppler ultrasonography imaging reveals that 
anti-P3 Abs prevent the HFD-induced arterial 
resistance index in the carotids of rabbits 
B-mode ultrasound images of rabbit carotid 
arteries did not show thickening or calcification indi-
cative of the presence of atherosclerotic lesions. Our 
available technology was not suitable for performing 
high-resolution studies (40-50 MHz) capable of 
detecting early atherosclerotic lesions in carotids. 
Doppler measurements were used to obtain the arter-
ial resistance index (ARI), an indirect hemodynamic 
parameter that indicates the resistance to blood flow 
in a vascular bed distal to the points of measurement: 
the systolic (1, 3, and 5), diastolic (2, 4, and 6), and 
pulse frequency measurement points (vertical dotted 
lines) (marked in Figure 10A). ARI was measured at 
baseline (pre-diet) and after one month of feeding 
rabbits HFD (post-diet) into the external and internal 
carotids from the IrP and P3-immunized rabbits. 
There were no differences in terms of the basal 
measurements between the groups. HFD increased 
ARI in both the external and internal carotid arteries 
of the IrP rabbits. However, in the P3-immunized 
rabbits, HFD only slightly induced ARI in the internal 
carotid artery (Figure 10B). As in the aorta, HFD 
dramatically induced cholesteryl ester accumulation 
in the carotids of IrP rabbits and anti-P3 Abs 
significantly reduced CE accumulation in the external 
but not in the internal carotid artery (Figure 10C). 
 
 
Figure 8. HFD serum from control and IrP serum, but not P3 serum, dramatically increased intracellular CE and pro-inflammatory mediators in human 
coronary vascular smooth muscle cells. Quiescent human coronary vascular smooth muscle cells (hcVSMC) were exposed to serum from the different groups (0.5%, 2 
hours). Cells were then exhaustively washed and collected in NaoH 0.1N for lipid extraction or in lysis buffer for Western blot analysis. A) Representative TLC and bar graphs 
showing the cholesteryl ester (CE) /free cholesterol ratio. Representative Western blot analysis of LRP1, SREBP-2, TNFR1, pNF-kB (p65), total NF-kB (p65), and a-actin bands 
(B) and bar graphs showing band quantification of LRP1, SREBP-2 and TNFR1 normalized by a-actin (C,D,E) and pNF-kB (p65)/total NF-kB (p65) ratio (F). Results are shown as 
mean ± SD of three experiments performed in duplicate. *P<0.005 versus chow serum; #P<0.005 versus control or IrP-serums. 






Figure 9. P3 immunization counteracts aortic 18F-FDG uptake induced by HFD in rabbits. (A) Representative PET/CT longitudinal images of the aorta in control 
and P3 immunized rabbits fed HFD. (B) Graphs showing the SUVmean progression from pre-diet to post-diet time points in the upper and middle parts of the aorta in HFD-fed 
rabbits (IrP and P3 groups) (N=6/group). *P<0.005 versus pred-diet; #P<0.005 versus IrP-rabbits. 
 
Figure 10. P3 immunization reduces the HFD-induced arterial resistance index (RI) and cholesteryl ester content in the carotids of rabbits. (A) 
Representative image of Eco Pulsed-Wave Doppler in the external carotid of rabbits. The systolic (1, 3 and 5), diastolic (2, 4 and 6), and pulse frequency measurement points 
(vertical dotted lines) are marked. (B) Arterial resistance index (ARI) was measured at baseline (pre-diet) and after 1 month of HFD feeding (post-diet) in external and internal 
carotids by Doppler ultrasonography in IrP and P3 groups (N=4/group). (C) Representative thin-layer chromatography of external and internal carotids and bar graphs showing 
the cholesteryl ester (CE)/free cholesterol (FC) ratio in carotids. Results are shown as mean ± SD. ***P<0.001, P3 versus control. *P<0.005 versus pred-diet; #P<0.005 versus 
IrP-rabbits.  






In this study, we revealed the significant 
reduction of two surrogate markers of atherosclerosis, 
aortic 18F-FDG cellular metabolism and carotid 
resistance index, upon the P3 immunization of 
rabbits. Immunohistochemical, confocal, and molecu-
lar studies showed that P3 immunization efficiently 
counteracted the formation of fatty streaks due to the 
high efficacy of Anti-P3 Abs in preventing foam cell 
formation and their coupled pro-inflammatory 
signaling involved in monocyte recruitment and 
VSMC migration (summarized in the graphical 
abstract, Fig. 11).  
Previous studies have consistently shown that 
LRP1 plays a crucial role in the maintenance of the 
vascular function and in atheroprotection due to its 
participation in signaling pathways that limit the 
vascular smooth muscle cell proliferative activity 
[12,13], apoptosis/efferocytosis and the pro-inflam-
matory signal of macrophages [14–16].The essential 
LRP1’s role in signaling prompted us to develop 
antibodies with capacity to specifically block the 
binding of aggregated LDL. In the present study, we 
show that Anti-P3 Abs normalized aortic LRP1 levels 
until the levels found in the aorta of chow fed rabbits. 
Therefore, this strategy to modulate LRP1 function 
should not alter the binding of essential LRP1 ligands 
and coactivators. 
 
HFD is known to promote atherosclerosis. Here, 
we found that, in agreement with previous studies 
[32,36], one month of HFD strongly promoted 
hypercholesterolemia and led to early atherosclerotic 
lesions or fatty streaks in NZW rabbits. In our rabbit 
experimental model, HFD increased circulating CE 
levels to aproximately 55 mM (2115 mg/dL), mainly 
transported by VLDL and LDL in the rabbit serum. 
Considering that the percentage of the protein in 
lipoproteins is similar to humans, LDL and VLDL in 
HFD-fed rabbits are extremely enriched in cholesteryl 
esters compared to human LDLs. In fact, the exposure 
of hMΦ and hcVSMC to HFD serum (0.5%) for only 2 
hours caused a tremendous intracellular CE 
accumulation, in agreement with the high CE 
accumulation that we observed in the aorta of this 
rabbit model. In line with our results in rabbits, an 
increased atherogenicity of large CE-enriched 
ApoB-100 lipoproteins has been previously reported 
in monkeys and pigs [37,38]. Remarkably, large LDLs 
have been associated with increased coronary artery 
disease in humans [39,40]. The excessive cholesteryl 
ester load of these lipoproteins per se seems not to be a 
primary factor determining their increased 
atherogenicity. Core cholesteryl ester and triglyceride 
seem to cause serious alterations in ApoB-100 
conformation, a key determinant of the LDL affinity 
by the LDLR [41,42]. Here, the high capacity of rabbit 
CE-enriched ApoB-100 lipoproteins to cause 
intracellular CE accumulation in human macrophages 
 
 
Fig. 11. Graphical Abstract 





and VSMC suggest that they are not taken up through 
the LDLR, a receptor downregulated by intracellular 
CE levels. Unexpectedly, anti-P3 Abs, designed to 
inhibit agLDL, not only counteracted CE 
accumulation in the rabbit vasculature, where LDL 
aggregation could have been facilitated by 
proteoglycans of the arterial intima, but also in hMΦ 
and hcVSMC that have been directly exposed to 
VLDL and LDL of the rabbit serum. The high efficacy 
of Anti-P3 Abs to block serum-induced hMΦ and 
hcVSMC cholesteryl ester loading suggest that rabbit 
large VLDL and/or LDL (CE-enriched ApoB-100 
lipoproteins) could be interacting with the human 
LRP1, probably through the same domain than 
aggregated LDL. Futher molecular studies are indeed 
required to know how CE-enriched large VLDLs 
and/or LDLs influence ApoB-100 conformation and 
whether the epitope of ApoB-100 generated in these 
lipoproteins share structural similarities with that 
generated in aggregated LDL. An important challenge 
for future research will be to design molecular tools 
suitable to reduce the vascular impact of the majority 
of atherogenic lipoproteins.  
Differently to aorta, where HFD only 
upregulates vascular cholesteryl ester content, HFD 
increased both hepatic cholesteryl esters and 
triglycerides. The differential impact of HFD serum in 
the neutral lipid content of aorta and liver could be 
associated to the particular lipoproteins that mainly 
interact with vascular and hepatic tissues. In vascular 
cells (macrophages and VSMC), LRP1 supposedly 
interacts greatly with agLDL [4–6]. In hepatic cells, 
LRP1 mainly interacts with ApoE-enriched 
lipoproteins such as chylomicrons [43]. It is known 
that ApoB-100 and ApoE interact with LRP1 receptor 
through different clusters. The new epitope generated 
in ApoB-100 during LDL aggregation interacts with 
cluster II (CR9 domain) [24] while ApoE interacts with 
cluster III (domain CR17) [44,45]. The different 
lipoproteins that reach aortas and livers may explain 
why P3 immunization reduces cholesteryl ester 
accumulation in the vasculature (aorta and carotids) 
but not in liver. The CR9 and CR17 domains are so 
spatially distant that it is structurally impossible for 
anti-P3 antibodies to cause any effect on the binding 
of ApoE-enriched lipoproteins. This could explain 
why P3 immunization did not exert any effect on the 
HFD-induced neutral lipid accumulation in the liver. 
The liver is a key organ that modulates whole-body 
lipid and lipoprotein metabolism and consequently 
circulating lipid and lipoprotein profile [46]. 
Therefore, the lack of impact of the Anti-P3 Abs in the 
hepatic neutral lipid content could be a determinant 
of the similar lipoprotein profile between groups. 
Molecular, immunohistochemical and confocal 
microscopy experiments showed that Anti-P3 Abs 
decreased HFD-induced TNFR1 overexpression in 
vasculature and cells. Macrophage-foam cells have 
been reported to secrete extracellular vesicles that 
determine the proliferative and migratory capacity of 
SMC [47]. Moreover, TNFR1 promotes monocyte 
recruitment and SMC proliferation in the 
pro-atherosclerotic arterial wall [23]. Therefore, the 
reduced TNFR1 levels that we observed in Anti-P3 
treated macrophages and VSMCs could indeed 
contribute to limit the recruitment of monocytes and 
VSMCs into the arterial intima. 
The impact of HFD on NF-kB (p65) phosphory-
lation reported in this study is in line with previous 
results showing that an excessive input of nutrition 
activates NF-kB signaling in macrophages [48]. Simi-
lar HFD effects were observed in the phosphorylation 
of NF-kB (p65) phosphorylation in VSMC. The high 
efficiency of Anti-P3 Abs to counteract HFD-induced 
NF-kB (p65) phosphorylation in hMΦ and hcVSMC, 
suggest a high potential of these Abs to modulate 
atherosclerosis. Abbate’s group has elegantly shown 
that, by counteracting NF-kB pro-inflammatory 
signaling, LRP1 activation with SP16 agonist leads to 
a cardioprotective signal that reduces infarct size 
[20,21]. SP16 has been designed on the basis of the 
motif present in protease-inhibitor complexes, which 
have been reported not to be recognized by the 
consecutive CR8/CR9 modules of cluster II [25]. The 
specific interaction of anti-P3 Abs with CR9 domains 
ensures high specificity of effects, and importantly, 
guarantees zero interference with the agonists of the 
LRP1 anti-inflammatory signaling. Of note that 
anti-P3 Abs did not exert any effect on these basal 
LRP1 levels, suggesting that Anti-P3 Abs reduced 
HFD-induced pro-inflammatory signaling without 
disturbing the atheroprotective LRP1 signaling in the 
vasculature.  
Taken together, our results highlight the 
strategic therapeutic value of Anti-P3 Antibodies to 
inhibit diet-induced cellular cholesteryl ester loading 
and coupled inflammation in the vasculature. 
In line with previous studies showing that 
18F-FDG uptake reaches maximal values during early 
foam cell formation [35], in the current study, we also 
showed that the anti-atherosclerotic efficiency of P3 
immunization on early lesions can be tracked by PET/ 
CT. Complementary confocal microscopy analysis 
showed that reduced 18F-FDG uptake in the aorta of 
P3-immunized rabbits occurred concomitantly with a 
reduced presence of macrophages and SMCs in the 
arterial intima. Although cellular metabolic activity in 
PET/CT has been assumed to be mainly caused by the 
high number of macrophages in atherosclerotic 
plaques [28], more recent studies have demonstrated 





that SMCs also play a crucial role in plaque PET/CT 
activity due to their high capacity to take up glucose 
when exposed to pro-inflammatory cytokines [49].  
While imaging for the detection of atherosclero-
tic lesions at different stages has been extensively 
used for rabbit aortas, less investigated has been the 
impact of HFD on the development of atherosclerosis 
in carotids of this animal model, and especially 
through imaging techniques. Here, we showed that 
one month of HFD increased the resistance index (RI) 
of both external and internal carotids despite the lack 
of direct evidence of atherosclerotic plaques in 
carotids. In carotid arteries, a significant correlation 
between RI and the degree of generalized atheroscler-
osis has been previously shown in humans [50]. Here, 
we demonstrated the efficacy of P3-immunization in 
reducing carotid RI, although the effect was different 
between the external and internal carotids (higher for 
the external carotids). In fact, further carotid lipidic 
analysis showed that P3 immunization reduced 
cholesteryl ester accumulation on the external but not 
on the internal carotid. Differential anatomy and 
hemodynamics could likely explain the differential 
impact of P3 immunization on these carotids. On the 
basis of aortic PET/CT and carotid Doppler ultrason-
ography, our results revealed that P3 immunization 
efficiently reduces HFD-induced atherosclerosis in 
rabbits, at least in the early stages. Moreover, these 
results suggested that PET/CT and ultrasonography 
are imaging techniques that can track the effect of 
potential therapeutic P3 immunizations in other 
translational in vivo models and in humans.  
Limitations of the study  
The main limitations of this study were that the 
efficacy of P3 immunization was not analyzed in the 
endothelium despite the crucial role of endothelial 
lrp1 in atherosclerosis, glucose sensitivity and lipid 
profiles [51]. Recently, it has been reported the 
feasibility of a surface-enhanced Raman scattering- 
antibody-functionalized gold nanoprobes (SERS- 
BFNP) molecular imaging platform for non-invasive 
detection of adhesion molecules in the endothelium of 
atherosclerotic lesions in in vivo models [52]. In 
addition, the efficacy of P3 immunization was only 
tested in early atherosclerotic lesions despite the high 
relevance of the interaction of VSMC with LDL for the 
vulnerability of the atherosclerotic plaques [53]. 
Finally, the technology used in the present study to 
detect the presence of atherosclerotic plaques in 
carotids has certain limitations.  
Conclusions 
In conclusion, our study demonstrates that, by 
specifically blocking LRP1-mediated intracellular CE 
accumulation in vascular cells, Anti-P3 Abs 
counteract cellular pro-inflammatory signals that 
allow for the recruitment of monocytes and VSMC 
into the arterial intima of a rabbit model of 
HFD-induced atherosclerosis. Moreover, anti-P3 Abs 
are extremely effective to stop foam cell formation 
from human macrophages and human coronary 
vascular smooth muscle cells and the efficacy of P3 
immunization can be tracked using non-invasive 
imaging techniques such as PET/CT and Doppler 
ultrasonography. These both aspects confer an 
enormous translational potential to Anti-P3 Abs.  
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